Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 USD | -0.66% | +14.59% | -57.11% |
Apr. 26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
Apr. 12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Financials (USD)
Sales 2024 * | 282M | Sales 2025 * | 386M | Capitalization | 393M |
---|---|---|---|---|---|
Net income 2024 * | -185M | Net income 2025 * | -89M | EV / Sales 2024 * | 2.49 x |
Net Debt 2024 * | 309M | Net Debt 2025 * | 230M | EV / Sales 2025 * | 1.61 x |
P/E ratio 2024 * |
-1.82
x | P/E ratio 2025 * |
-3.57
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.53% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -0.66% | ||
1 week | +14.59% | ||
Current month | +4.43% | ||
1 month | -16.41% | ||
3 months | -29.80% | ||
6 months | -55.33% | ||
Current year | -57.11% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 3.77 | -0.66% | 1,256,213 |
24-05-01 | 3.795 | +5.12% | 1,960,600 |
24-04-30 | 3.61 | -2.17% | 2,111,319 |
24-04-29 | 3.69 | +8.53% | 3,223,918 |
24-04-26 | 3.4 | +3.34% | 2,280,332 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.11% | 393M | |
-3.79% | 87.06B | |
+2.76% | 40.25B | |
-17.49% | 31.09B | |
+55.32% | 24.74B | |
-13.13% | 15.91B | |
-9.12% | 11.96B | |
-15.45% | 11.92B | |
-42.56% | 11.61B | |
+5.17% | 8.73B |
- Stock Market
- Equities
- RVNC Stock